Characterization of a Peptide Antibody Specific to the Adenylyl Cyclase-Associated Protein of *Acanthamoeba castellani*ni*

Min-Jeong Kim, Hae-Ahm Lee, Fu-Shi Quan, Hyun-Hee Kong, Eun-Kyung Moon

**INTRODUCTION**

*Acanthamoeba* keratitis (AK) is a rare infectious disease affecting the eye that can lead to permanent vision loss if not treated properly [1]. To prevent such disastrous consequences from occurring, a rapid and accurate AK diagnosis is crucial. In AK patients, bacterial or fungal coinfections are common. Members of the genera *Staphylococcus* and *Fusarium* were reported as the most common pathogens of bacterial and fungal origins encountered by AK patients, respectively [2,3]. Since symptoms of AK can be quite similar to those of bacterial and fungal keratitises, it is often misdiagnosed [4]. Therefore, the possibility of these pathogens co-inhabiting the cornea along with *Acanthamoeba* spp. should always be considered to deliver an accurate diagnosis and appropriate treatments.

Currently, most cases of AK have been diagnosed by confocal microscopy, corneal scrapings, *Acanthamoeba* culture on agar plates, polymerase chain reaction amplification, and histopathological examinations [5,6]. Immunoassays using specific antibodies are also important techniques for the detection of *Acanthamoeba*. Four monoclonal antibodies (AMEC1, AMEC3, MTAC1, and MTAC3) generated by mixtures of *A. castellanii* trophozoites and cysts of *A. castellanii* co-cultured with HCE cells. The ACAP antibody also specifically interacted with the trophozoites and cysts of 5 other *Acanthamoeba* species. These results indicate that the ACAP antibody of *A. castellanii* can specifically detect multiple AK-causing members belonging to the genus *Acanthamoeba* and may be useful for differentially diagnosing *Acanthamoeba* infections.

**Key words:** *Acanthamoeba*, diagnosis, adenylyl cyclase-associated protein
The application of CAP to detect parasitic organisms are extremely limited. Many studies have been conducted on CAP as a biomarker for early hepatocellular carcinoma [19]. In recent years, CAP2 is also a potential diagnostic biomarker for human gastric and cardiac muscles, brains, and skin [14]. CAP2 has specific expressions in skeletal and cardiac muscles, whereas CAP2 has specific expressions in skeletal and cardiac muscles, brains, and skin [14]. CAP2 is a biomarker with diagnostic and prognostic values in human gastric and breast cancer [17,18]. CAP2 is also a potential diagnostic biomarker for early hepatocellular carcinoma [19]. In recent years, many studies have been conducted on CAP as a biomarker for the diagnosis of human diseases. However, studies reporting the application of CAP to detect parasitic organisms are extremely limited.

In our previous study, we found that the gene expression of ACAP of *A. castellanii* is upregulated to a greater extent in the pathogenic strain than in the non-pathogenic strain [20]. Based on this observation, we hypothesized that ACAP could be used to specifically detect pathogenic strains of *Acanthamoeba*. Thus, we produced a polyclonal peptide antibody targeting the ACAP of pathogenic *A. castellanii*, and evaluated its diagnostic potential. The objective of this study was to describe the production of ACAP antibodies and their specificities to several pathogenic *Acanthamoeba* spp. using enzyme-linked immunosorbent assay (ELISA), western blot analysis, and immunocytochemistry (ICC) assay.

**MATERIALS AND METHODS**

**Cell cultures**

Human corneal epithelial (HCE) cells (PCS-700–010) and *Acanthamoeba castellanii* Castellanii (ATCC 30868) were purchased from the American Type Culture Collection. *A. castellani*i Neff, *A. hatchetti*, *A. polyphaga*, *A. culbertsoni*, and *A. royreba* were kindly provided by Prof. Ho-Joon Shin at Ajou University (Suwon, Korea). *Fusarium solani*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* were obtained from the Korea Centers for Disease Control & Prevention (NCCP 32678, NCCP 16091, and NCCP 15920). HCE cells were cultured at 37˚C with 5% CO2 in endothelial cell growth medium kits (KGM BulletKit) (Lonza, Portsmouth, New Hampshire, USA). *Acanthamoeba* trophozoites were cultured in Peptone-Yeast-Glucose (PYG) media at 25˚C for 5 days, and cysts were induced in encystment media (95 mM NaCl, 5 mM KCl, 8 mM MgSO4, 0.4 mM CaCl2, 1 mM NaHCO3, and 20 mM Tris-HCl, pH 9.0) at 25˚C. *F. solani* was cultured using Sabouraud Dextrose (SD) media at 25˚C, and *P. aeruginosa* and *S. aureus* were cultured on Brain Heart Infusion (BHI) media at 37˚C incubators.

**Peptide antibody production of adenylyl cyclase-associated protein**

The peptide sequence of adenylyl cyclase-associated protein used as the immunogen is as follows: NH2-QRELKASQSK-KPDATTFG-C-COOH. Synthesized peptide and the antibody raised against the peptide were purchased from AbFRONTIER (AbFRONTIER, Seoul, Korea). Briefly, 2 NZW rabbits were injected intradermally with 1.0 mg of peptide-KLH conjugates with complete Freund’s adjuvant on days 0, and 0.5 mg of the peptide with incomplete Freund’s adjuvant on days 28, 42, and 56. The animals were bled on days 35 and 49. After the third immunization, the sera titer was assessed using an indirect ELISA with the peptide-BSA conjugates as coating antigens until the titer plateaued. After the last immunization, blood samples were acquired by cardiac puncture from each rabbit.

**Enzyme-linked immunosorbent assay (ELISA)**

*Acanthamoeba*-specific antibody responses against *Acanthamoeba* cell lysates (10^2 to 10^3 μg/ml) from serially diluted sera (1:5 to 1:50,000) were determined using ELISA as described previously [11]. Briefly, 96-well plates were coated with antigens in carbonate coating buffer overnight at 4˚C. Plates were washed 3 times with PBST and blocked with 0.2% gelatin for 2 hr at 37˚C. Sera diluted in PBS were inoculated into wells and incubated at 37˚C for 1 hr. Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG or IgA (Sigma-Aldrich, St. Louis, Missouri, USA) was added at 1:1,000 dilution in PBS and incubated at 37˚C for 1 hr. O-phenylenediamine substrate (Zymed, San Francisco, California, USA) was dissolved in citrate-phosphate buffer with H2O2. The optical density values at 450 nm were read using EZ Read 400 microplate reader (Biochrom Ltd., Cambridge, UK). The sera of the immunized mice were used as a negative control.

**Western blot**

To verify the specificity of the ACAP antibody, western blotting was conducted using HCE cells, *A. castellanii*, *F. solani*, *S. calculus*, and *S. aureus*. The sera of the immunized mice were used as a negative control.
aureus, and P. aeruginosa [11]. Briefly, each cell lysates were confirmed on 10% SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked with 5% skim milk in TBST for 2 hr and incubated overnight at 4°C with the ACAP antibody (1:1,000). The membrane was washed with TBST and probed with HRP-conjugated anti-rabbit IgG (Sigma-Aldrich) (1:5,000) for 1 hr at RT. Bands were developed in the darkroom using Clarity Enhanced Chemiluminescence reagent (Thermo Fisher, Waltham, Massachusetts, USA) on x-ray films.

Immunocytochemistry (ICC)

To confirm the specificity of the ACAP antibody, an immunocytochemistry assay was conducted using HCE cells, Acanthamoeba spp. trophozoites, and cysts [11]. HCE cells (3 × 10⁵ cells) were cultured on sterile cover glass in a 6-well plate. The following day, they were co-cultured with Acanthamoeba trophozoites (5 × 10⁵ cells), and cysts (5 × 10⁵ cells) for 5 hr at 37°C with 5% CO₂. After washing with PBS, the cells were fixed with ice-cold 100% methanol for 5 min at RT. Cells were washed and permeabilized with PBST for 10 min at RT. The cells were washed and blocked using blocking buffer (1% bovine serum albumin and 22.52 mg/ml glycine in PBST) for 30 min at RT. The cells were incubated overnight at 4°C with ACAP antibody (1:200) in blocking buffer and probed with CruzFluor™ 555 (CFL 555)-conjugated anti-rabbit IgG (1: 400; Santa Cruz, Dallas, Texas, USA) for 1 hr at RT. After washing, cells were stained with VECTASHIELD mounting medium (Abcam, Burlingame, California, USA) and observed under a fluorescent microscope (Leica DMi8, Wetzlar, Germany).

Statistical analysis

Student’s t-test was performed using GraphPad Prism version 5 (San Diego, California, USA). Data are expressed as mean ± SD. Statistical significance between the means of groups was denoted using an asterisk. P values less than 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, and ***P < 0.001).

RESULTS

Sequence analysis of ACAP of A. castellanii for antigen preparation

The adenylyl cyclase-associated protein (ACAP) of A. castellanii consists of 1,458 bp and encodes 485 amino acids with a calculated mass of 53.35 kDa (GeneBank: MW683237.1). To design a peptide antigen with optimal antigenicity, amino acid sequences of ACAP of A. castellanii were compared with those of Homo sapiens (ACAP1 and ACAP2), F. oxysporum, S. aureus, and P. aeruginosa (Fig. 1). Based on the secondary structure

Fig. 1. Multiple sequence alignment of ACAPs. Aligned amino acid sequences of ACAP from A. castellanii (Ac_ACAP), H. sapiens (Hs_ACAP1 and Hs_ACAP2), F. oxysporum (Fo_ACAP), S. aureus (Sa_ACAP), and P. aeruginosa (Pa_ACAP) were compared. The deduced amino acid sequences were aligned by using ClustalW, and the degree of conservation is represented by different shading. The boxed sequence was used to raise the anti-ACAP polyclonal antibody.
analysis, hydrophobicity, and amino acid homology search, amino acids at positions 90-109 were selected for peptide antibody production (boxed area in Fig. 1). Amino acid sequence homology results showed that ACAP of *A. castellanii* showed 40.6%, 40.2%, 15.5%, 24.3%, and 19.2% similarity with those of *H. sapiens* (ACAP1 and ACAP2), *F. oxysporum*, *S. aureus*, and *P. aeruginosa*, each respectively (Table 1).

**Antibody responses to ACAP antigen**

ELISA was performed to titrate *A. castellanii*-specific IgG and IgA antibodies in low dilutions of immunized rabbit serum (Fig. 2). *Acanthamoeba*-specific IgG and IgA antibody responses could be observed until 1:5,000 and 1:50 dilutions of immune sera, respectively (Fig. 2A, B). To establish the sensitivity of the ACAP antibody, antibodies were reacted with the serially diluted cell lysates of *A. castellanii*. The detection ranges for the *Acanthamoeba*-specific IgG and IgA were as low as $10^{-2}$ μg/μl and $10^{-3}$ μg/μl of cell lysates, respectively (Fig. 2C, D). These results indicated that a high level of anti-*Acanthamoeba* IgG antibody and a low level of anti-*Acanthamoeba* IgA antibody responses could be elicited by the *A. castellanii* ACAP immune sera.

**Specificity of ACAP peptide polyclonal antibody**

To investigate the specificity of the anti-ACAP peptide polyclonal antibody, western blot analysis was performed using cell lysates of HCE cells, *A. castellanii*, *F. solani*, *S. aureus*, and *P. aeruginosa* (Fig. 3). The ACAP antibody reacted with *A. castellanii*, while such strong interactions were not observed from HCE cells, *F. solani*, *S. aureus*, and *P. aeruginosa*. The estimated sizes of the ACAP of HCE cells, *A. castellanii*, *F. oxysporum*, *S. aureus*, and *P. aeruginosa* were 52.25 kDa, 53.35 kDa, 41.58 kDa, 50.87 kDa, and 41.58 kDa, respectively.

### Table 1. Identities of ACAP amino acids as determined by BLASTP

| Name    | Accession No. | Length (aa) | Identities (%) |
|---------|---------------|-------------|----------------|
| Ac_ACAP | QVH35979.1    | 485         | 100            |
| Hs_ACAP1| NP_006358.2   | 475         | 40.6           |
| Hs_ACAP2| NP_001317431.2| 474         | 40.2           |
| Fo_ACAP | EWY80337.1    | 378         | 15.5           |
| Sa_ACAP | CRL38334.1    | 197         | 24.3           |
| Pa_ACAP | OIQH71188.1   | 378         | 19.2           |

**Fig. 2.** Antibody responses in rabbit antiserum to ACAP of *A. castellanii*. The ACAP-specific IgG and IgA antibody titers were measured by ELISA (A, B). Sera collected from the ACAP immunized rabbits were diluted at a ratio of 1:50,000. Sensitivities of these antibodies were assayed by serially diluted cell lysates of *A. castellanii* (C, D). Asterisks denote statistically significant differences between positive (●) and negative (○) serum (**$P<0.01$ and ***$P<0.001$).
kDa, 21.67 kDa, 41.58 kDa, each respectively (Table 1). Some faint bands appeared when *F. solani*, *S. aureus*, and *P. aeruginosa* lysates were probed with the ACAP antibody, but size differences indicate that they were of non-specific origin.

To confirm the specificity of ACAP antibody to *A. castellanii* trophozoites and cysts, immunocytochemistry was performed using HCE cells co-cultured with *Acanthamoeba* (Fig. 4). The nuclei of HCE cells were stained with DAPI (blue), but HCE cells remained unstained with ACAP antibody labeled with CFL fluorophore (red). However, *A. castellanii* trophozoites (top row) and cysts (bottom row) showed strong interaction with the ACAP antibody (red). DAPI-stained nuclei of *Acanthamoeba* were faintly visible because the size of *Acanthamoeba* nuclei is much smaller than that of HCE cells. This result demonstrated that the ACAP peptide antibody of *A. castellanii* specifically detected the trophozoites and cysts of *A. castellanii*.

The specificity of ACAP Antibody to other *Acanthamoeba* spp.

For further verification of the specificity of the ACAP antibody, immunocytochemistry was performed using 5 different species of *Acanthamoeba*. (Table 2; Fig. 5). The trophozoites and cysts of *A. castellanii Neff*, *A. hatchetti*, *A. polyphaga*, *A. culbertsoni*, and *A. royea* interacted with ACAP antibodies. However, the cysts of *A. polyphaga* did not specifically react with the

![Table 2. Specific detection of 5 reference *Acanthamoeba* spp. by immunocytochemistry.](image)

Table 2. Specific detection of 5 reference *Acanthamoeba* spp. by immunocytochemistry.

| Species                  | Pussard-Pons group | Trophozoites | Cysts |
|--------------------------|--------------------|--------------|-------|
| *A. castellanii Neff*    | II                 | +            | +     |
| *A. hatchetti*           | II                 | +            | +     |
| *A. polyphaga*           | II                 | +            | ±     |
| *A. culbertsoni*         | III                | +            | +     |
| *A. royea*               | III                | +            | +     |

![Fig. 3. Specificity of the anti-ACAP antibody. Antibody specificity was determined by western blot analysis using cell lysates from different organisms. Lane 1; HCE cells, Lane 2; *A. castellanii*, Lane 3; *F. solani*, Lane 4; *S. aureus*, Lane 5; *P. aeruginosa.*](image)

Fig. 3. Specificity of the anti-ACAP antibody. Antibody specificity was determined by western blot analysis using cell lysates from different organisms. Lane 1; HCE cells, Lane 2; *A. castellanii*, Lane 3; *F. solani*, Lane 4; *S. aureus*, Lane 5; *P. aeruginosa.*

![Fig. 4. Immunocytochemistry assay of anti-ACAP antibody. HCE cells and *A. castellanii* trophozoites and cysts were co-cultured and observed under a fluorescent microscope. Bright-field, DAPI staining (blue), ACAP antibody combined with CFL-conjugated secondary antibody (red), and merged images were acquired.](image)

Fig. 4. Immunocytochemistry assay of anti-ACAP antibody. HCE cells and *A. castellanii* trophozoites and cysts were co-cultured and observed under a fluorescent microscope. Bright-field, DAPI staining (blue), ACAP antibody combined with CFL-conjugated secondary antibody (red), and merged images were acquired.
ACAP antibody. This result showed that the ACAP antibody of A. castellanii was capable of detecting various species of Acanthamoeba trophozoites and cysts.

**DISCUSSION**

For effective treatment of AK, an accurate diagnosis in the early stages of infection is essential. Accordingly, sensitive and rapid differential diagnostic methods for AK have been studied. Currently, several studies investigating the diagnostic potential of antibody-based methods for AK have been reported [7-11]. In this study, we produced a polyclonal peptide antibody against the ACAP of A. castellanii and studied its specificity. This antibody was highly specific to 6 different species of Acanthamoeba.

*Acanthamoeba* exists either as an infective trophozoite form or a dormant cyst form. It is thought that trophozoite-derived proteases contribute to penetration and degradation of the...
stroma, and the severe pain associated with AK [21]. Encystation prolongs the infection and renders the Acanthamoeba highly resilient to therapeutic agents [22]. It has been reported that Acanthamoeba cysts are capable of surviving over 24 years [5]. Currently, the Gram stain and Giemsa stain are widely used for the rapid detection of Acanthamoeba cysts in corneal scrapings [23]. However, false-negative and false-positive results can occur if the Acanthamoeba spp. cannot be differentiated from surrounding tissue cells and other coinfecting pathogens [23]. We have previously reported the Acanthamoeba-specific antibodies targeting the IPNH and CM of A. castellanii [10,11]. Although these studies revealed that these antibodies could specifically identify trophozoites of Acanthamoeba spp. from other causes of keratitis, our previous studies did not investigate their diagnostic potential against cysts of Acanthamoeba spp. The ACAP participates in the activation of adenylyl cyclase, which is upregulated and induces prespore differentiation in Dictyostelium slugs [14,26]. It is presumed that the ACAP is also involved in the cyst formation of Acanthamoeba.

The ACAP antibody described in this study strongly reacted with both trophozoites and cysts of the aforementioned 6 Acanthamoeba spp (Figs. 4, 5). Therefore, the presence of Acanthamoeba trophozoites and cysts could be easily confirmed by using this antibody.

Acanthamoeba spp. is distributed in natural environments. It has been reported that 50% to 100% of healthy people possess Acanthamoeba-specific antibodies [24,25]. However, AK patients have significantly higher anti-Acanthamoeba IgG antibody titers than healthy people [25]. In the present study, an immunized rabbit with ACAP of A. castellanii produced Acanthamoeba-specific high IgG but low IgA (Fig. 2). Acanthamoeba-specific IgG and IgA were demonstrated to be sensitive with a detection limit as low as 10 ng/µl and 1 µg/µl of Acanthamoeba cell lysate, respectively (Figs. 2C, D). Therefore, if Acanthamoeba is present in corneal scrapings or ocular secretions of AK patients, it is believed that Acanthamoeba can be sufficiently detected with this antibody.

Over 20 species of Acanthamoeba have been identified, of which, 8 species (A. castellanii, A. polyphaga, A. roiyreba, A. culbertsoni, A. hachetti, A. griffin, A. quina, and A. lugdunensis) could cause keratitis, with A. castellanii and A. polyphaga being the most common causes of AK [22]. In the present study, we used 6 species of Acanthamoeba (A. castellanii Castellani, A. castellanii Neff, A. hachetti, A. polyphaga, A. culbertsoni, and A. roiyreba). Immunocytochemistry results revealed that the ACAP antibody reacted with all these Acanthamoeba spp (Figs. 4, 5). It would be nice to add the results of detecting A. griffin, A. quina, and A. lugdunensis by ACAP antibody. In addition, it is needed that the AK mouse model or human corneal scrapes can be used to detect Acanthamoeba spp. in future studies.

In summary, we generated a polyclonal peptide antibody against the ACAP protein of A. castellanii that specifically detected 6 species of Acanthamoeba trophozoites and cysts. This result suggests its potential for developing a diagnostic method for AK.

ACKNOWLEDGMENT

This work was supported by the National Research Foundation of Korea (NRF) grant funded by Korea government (MIST) (No. 2020R1A2C1005345).

CONFLICT OF INTEREST

The authors declare no conflict of interest related to this study.

REFERENCES

1. Page MA, Mathers WD. Acanthamoeba keratitis: a 12-year experience covering a wide spectrum of presentations, diagnoses, and outcomes. J Ophthalmol 2013; 2013: 670242. https://doi.org/10.1155/2013/670242
2. Singh A, Sahu SK, Sharma S, Das S. Acanthamoeba keratitis versus mixed Acanthamoeba and bacterial keratitis: comparison of clinical and microbiological profiles. Cornea 2020; 39: 1112-1116. https://doi.org/10.1016/j.jco.2019.01.024
3. Raghavan A, Baidwal S, Venkatapathy N, Rammohan R. The Acanthamoeba-fungal keratitis study. Am J Ophthalmol 2019; 201: 31-36 https://doi.org/10.1016/j.ajo.2019.01.024
4. Fanselow N, Sirajuddin N, Yin XT, Huang AJW, Stuart PM. Acanthamoeba keratitis, pathology, diagnosis and treatment. Pathogens 2021; 10: 323. https://doi.org/10.3390/pathogens10030323
5. Szentmáry N, Daas L, Shi L, Laurik KL, Lepper S, Milioti G, Seitz B. Acanthamoeba keratitis-Clinical signs, differential diagnosis and treatment. J Curr Ophthalmol 2018; 31: 16-23. https://doi.org/10.1016/j.joco.2018.09.008
6. Sharma S, Athmanathan S, Ata-Ur-Rasheed M, Garg P, Rao GN. Evaluation of immunoperoxidase staining technique in the diagnosis of Acanthamoeba keratitis. Indian J Ophthalmol 2001; 49: 181-186
7. Turner ML, Cockerell EJ, Breton HM, Badenoch PR, Tea M, Coster DJ, Williams KA. Antigens of selected Acanthamoeba species detected with monoclonal antibodies. Int J Parasitol 2005;
8. Weber-Lima MM, Prado-Costa B, Becker-Finco A, Costa AO, Bil- lilad P, Furst G, de Moura JF, Alvarenga LM. *Acanthamoeba* spp. monoclonal antibody against a CPA2 transporter: a promising molecular tool for acanthamoebiasis diagnosis and encystment study. Parasitology 2020; 147: 1678-1688. doi:10.1017/S0031182020001778

9. Kang AY, Park AY, Shin HJ, Khan NA, Maciver SK, Jung SY. Production of a monoclonal antibody against a mannose-binding protein of *Acanthamoeba* culbertsoni and its localization. Exp Parasitol 2018; 192: 19-24. doi:10.1016/j.exppara.2018.07.009

10. Park SM, Lee HA, Chu KB, Quan FS, Kim SJ, Moon EK. Production of a polyclonal antibody against inosine-uridine preferring nucleoside hydrolase of *Acanthamoeba castellanii* and its access to diagnosis of *Acanthamoeba* keratitis. PLoS One 2020; 15: e0239867. doi:10.1371/journal.pone.0239867

11. Lee HA, Chu KB, Kim MJ, Quan FS, Kong HH, Moon EK. Chorismate mutase peptide antibody enables specific detection of *Acanthamoeba*. PLoS One 2021; 16: e0250342. doi:10.1371/journal.pone.0250342

12. Field J, Nikawa J, Broek D, MacDonald B, Rodgers L, Wilson IA, Lerner RA, Wigler M. Purification of a RAS-responsive adenylyl cyclase complex from *Saccharomyces cerevisiae* by use of an epitope addition method. Mol Cell Biol 1988; 8: 2159-2165. doi:10.1128/mcb.8.5.2159-2165.1988

13. Noegel AA, Rivero F, Albrecht R, Janssen KP, Köhler J, Parent CA, Schleicher M. Assessing the role of the ASP56/CAP homologue of *Dictyostelium discoideum* and the requirements for subcellular localization. J Cell Sci 1999; 112: 3195-3203.

14. Kakurina GV, Kolegova ES, Kondakova IV. Adenylyl cyclase-associated protein 1: structure, regulation, and participation in cellular processes. Biochemistry (Mosc) 2018; 83: 45-53. doi:10.1134/S0006297918010066

15. Hubbenstey AV, Mottillo EP. Cyclase-associated proteins: CAPacity for linking signal transduction and actin polymerization. FASEB J 2002; 16: 487-499. doi:10.1096/fj.01-0659rev

16. Zhang H, Gai P, Wu H, Wang C, Field J, Zhou GL. Mammalian adenylyl cyclase-associated protein 1 (CAP1) regulates coflin function, the actin cytoskeleton, and cell adhesion. J Biol Chem 2013; 288: 20966-20977. doi:10.1074/jbc.M113.484535

17. Li L, Fu LQ, Wang HJ, Wang YY. CAP2 is a valuable biomarker for diagnosis and prognosis in patients with gastric cancer. Pathol Oncol Res 2020; 26: 273-279. doi:10.1007/s12253-018-0450-4

18. Xu L, Peng S, Huang Q, Liu Y, Jiang H, Li X, Wang J. Expression status of cyclase-associated protein 2 as a prognostic marker for human breast cancer. Oncol Rep 2016; 36: 1981-1988. doi:10.1389/or.2016.5051

19. Fu J, Li M, Wu DC, Liu LL, Chen SL, Yun JP. Increased expression of CAP2 Indicates Poor Prognosis in Hepatocellular Carcinoma. Transl Oncol 2015; 8: 400-406. doi:10.1016/j.tranon.2015.08.003

20. Moon EK, Choi HS, Park SM, Kong HH, Quan FS. Comparison of proteins secreted into extracellular space of pathogenic and non-pathogenic *Acanthamoeba castellanii*. Korean J Parasitol 2018; 56: 553-558. doi:10.3347/kjp.2018.56.6.553

21. Clarke DW, Niederkorn JY. The pathophysiology of *Acanthamoeba* keratitis. Trends Parasitol 2006; 22: 175-180. doi:10.1016/j.pt.2006.02.004

22. Maycock NJ, Jayaswal R. Update on *Acanthamoeba* keratitis: diagnosis, treatment, and outcomes. Cornea 2016; 35: 713-720. doi:10.1097/ICO.0000000000000804

23. Sharma S, Garg P, Rao GN. Tear characteristics, diagnosis, and treatment of non-contact lens related *Acanthamoeba* keratitis. Br J Ophthalmol 2000; 84: 1103-1108. doi:10.1136/bjo.84.10.1103

24. Alizadeh H, Apte S, El-Agha MS, Li L, Hurt M, Howard K, Cavanaugh HD, McCulley JP, Niederkorn JY. Tear IgA and serum IgG antibodies against *Acanthamoeba* in patients with *Acanthamoeba* keratitis. Cornea 2001; 20: 622-627. doi:10.1097/00003226-200108000-00013

25. Walochnik J, Obwaller A, Haller-Schober EM, Aspöck H. Anti-*Acanthamoeba* IgG, IgM, and IgA immunoreactivities in correlation to strain pathogenicity. Parasitol Res 2001; 87: 651-656. doi:10.1007/s00436000412

26. Alvarez-Curto E, Saran S, Meima M, Zobel J, Scott C, Schaap P. cAMP production by adenylyl cyclase G induces prespore differentiation in *Dictyostelium* slugs. Development 2007; 134: 959-966. doi:10.1242/dev.02775